These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22149610)

  • 1. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
    Lampiris HW
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):13-20. PubMed ID: 22149610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
    Perry CM
    Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
    Olin JL; Spooner LM; Klibanov OM
    Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
    HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
    Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
    Marchand C
    Expert Opin Investig Drugs; 2012 Jul; 21(7):901-4. PubMed ID: 22571404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
    Schrijvers R; Debyser Z
    Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
    Manzardo C; Gatell JM
    AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
    German P; Warren D; West S; Hui J; Kearney BP
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
    Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stribild: a review of component characteristics and combination drug efficacy.
    Murrell DE; Moorman JP; Harirforoosh S
    Eur Rev Med Pharmacol Sci; 2015; 19(5):904-14. PubMed ID: 25807445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
    Temesgen Z
    Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elvitegravir/cobicistat, mirabegron, and linaclotide.
    Hussar DA; Martinez LN
    J Am Pharm Assoc (2003); 2012; 52(6):860-2. PubMed ID: 23229974
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-tablet regimens in HIV: does it really make a difference?
    Aldir I; Horta A; Serrado M
    Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
    Raffe S; Fisher M
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):427-35. PubMed ID: 25553805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.